Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Neisseria meningitidis Polysaccharide Capsule (Serogroups A, C, Y, W-135)
- Molecular classification
- Polysaccharide, Capsular Antigen
01
Overview
The polysaccharide capsule of *Neisseria meningitidis* is a crucial virulence factor that enables the bacterium to evade host immune responses and cause invasive diseases. Vaccines targeting the capsular polysaccharides of serogroups A, C, Y, and W-135 are highly effective in preventing meningococcal disease caused by these serotypes. The capsule consists of unique repeating polysaccharide units specific to each serogroup, which determine immunogenicity. These capsules are anchored to the outer membrane via lipid modification and diacylglycerols at their reducing ends. Quadrivalent vaccines targeting these four serogroups use purified capsular polysaccharides from each group as antigens.
- Other names
- Meningococcal Polysaccharide CapsuleN. meningitidis CapsuleCapsular PolysaccharideSerogroup A CapsuleSerogroup C CapsuleSerogroup Y CapsuleSerogroup W-135 Capsule
02
Mechanism of action
Vaccine-induced antibody production against capsular polysaccharides, leading to opsonization and complement-mediated killing of bacteria. Prevents bacterial colonization and invasion.
03
Biological functions
Immune evasionVirulenceCell surface componentAdhesion
04
Disease associations
MeningitisSepticemiaInvasive Meningococcal DiseaseInfection
05
Safety considerations
Rare adverse reactions to vaccines (e.g., injection site reactions, fever)Vaccine efficacy can vary depending on age and immune status of the recipientLack of protection against non-vaccine serogroups (e.g., B, X)
06
Interacting drugs
Quadrivalent Meningococcal Conjugate Vaccines (e.g., MCV4)
1 more in the full profile.
07
Biomarkers
Capsular polysaccharide serotype identification in clinical samplesAntibody titers against serogroups A, C, Y, and W-135 post-vaccination
Beyond the preview
Go deeper on Neisseria meningitidis Polysaccharide Capsule (Serogroups A, C, Y, W-135).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Neisseria meningitidis Polysaccharide Capsule (Serogroups A, C, Y, W-135).